Physician profile
Darin D Checketts
NPI 1639158512
$11,204.52
in general payments reported to CMS, 2019-2025
58 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,216 · 2020: $1,395 · 2021: $1,965 · 2022: $1,898 · 2023: $1,390 · 2024: $1,930 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,731.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,286.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,018.73 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $871.92 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $850.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $828.07 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $754.20 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $649.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $646.49 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $407.67 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $330.00 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $291.36 | 2019-2024 | Spravato, Xarelto |
| Abbott Laboratories | $272.45 | 2020-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $264.11 | 2019-2024 | |
| Amarin Pharma, INC. | $264.09 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $240.82 | 2020-2025 | Trintellix |
Show all 57 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Checketts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.